United Therapeutics
unither.comTotal trials
83
Active
8
Phase 3
31
Total enrollment
14,677
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 6 of 6 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Oral Treprostinil | — | — | 10 | ||||
| Parenteral Treprostinil | — | — | — | — | — | 1 | |
| Inhaled Treprostinil | — | — | — | 11 | |||
| Ralinepag | — | — | — | — | 4 | ||
| GGTA1 KO Thymokidney | — | — | — | — | — | 1 | |
| 10 GE Xenokidney | — | — | — | — | — | 1 |
Next readouts
- 2026-04-30
- 2026-06
- 2026-12
- 2027-03
- 2027-11
- 2028-10
- 2029-03
Top conditions
- Pulmonary Arterial Hypertension39
- Pulmonary Hypertension22
- Interstitial Lung Disease8
- Hypertension, Pulmonary7
- PAH5
- Chronic Obstructive Pulmonary Disease3
- Hypertension3
- Familial Primary Pulmonary Hypertension3
Frequently asked questions about United Therapeutics
- How many clinical trials does United Therapeutics have on ClinicalTrials.gov?
- United Therapeutics is listed as the lead sponsor on 83 clinical trials in ClinicalTrials.gov, 8 of which are currently active (recruiting, enrolling, or ongoing).
- How many of United Therapeutics's trials are in Phase 3?
- 31 of United Therapeutics's trials are in Phase 3, spread across 6 active drug programs.
- What therapeutic areas does United Therapeutics focus on?
- United Therapeutics's most-studied conditions on ClinicalTrials.gov are Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Hypertension, Pulmonary, PAH.
- When are United Therapeutics's next clinical trial readouts?
- United Therapeutics has 7 upcoming primary-completion readouts tracked here; the soonest is “A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension”, expected around 2026-04-30.